Impact of Periodontal Disease on Outcomes in Diabetes
1 other identifier
observational
250
1 country
1
Brief Summary
This study examines how periodontal disease affects the complications of diabetes and how treatment for periodontal disease affects biomarkers associated with the complications of diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 23, 2014
CompletedFirst Posted
Study publicly available on registry
November 13, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedDecember 2, 2015
November 1, 2015
1.6 years
October 23, 2014
November 30, 2015
Conditions
Outcome Measures
Primary Outcomes (3)
Changes in hemoglobin A1c
At enrollment, 3 months after enrollment and 6 months after enrollment.
biomarkers of inflammation (high sensitivity C - reactive protein and tumor necrosis factor - alpha)
At enrollment, 3 months after enrollment and 6 months after enrollment.
markers of bone turnover (bone specific alkaline phosphatase and C terminal
At enrollment, 3 months after enrollment and 6 months after enrollment.
Secondary Outcomes (1)
Evaluation of the relationship between periodontal disease and diabetes control and complications
At enrollment only
Eligibility Criteria
University of Nevada School of Medicine (Las Vegas) Internal medicine and endocrinology clinics
You may qualify if:
- Answers on the questionnaire suggesting POD or gingivitis.
- At least 16 teeth in place
- On a stable treatment for their diabetes
- Hemoglobin A1c between 6 and 10
You may not qualify if:
- Treatment with anti-inflammatory medications
- Cigarette smoking
- Treatment with thiazolidinediones
- Previous diagnosis of osteoporosis or treatment for osteoporosis with FDA approved agents.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Nevada School of Medicine
Las Vegas, Nevada, 89102, United States
Related Publications (2)
1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
BACKGROUNDBoyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29.
PMID: 20969750BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kenneth E Izuora, MD, MBA
University of Nevada, Reno
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 23, 2014
First Posted
November 13, 2014
Study Start
November 1, 2013
Primary Completion
June 1, 2015
Study Completion
June 1, 2015
Last Updated
December 2, 2015
Record last verified: 2015-11